Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 23, 2010

NCI Awarded Advanced Targeting Systems $3M to Advance Preclinical Cancer Pain Candidate

  • Advanced Targeting Systems received $3 million from the NCI to advance SP-SAP over the next two years into clinical trials for cancer pain. SP-SAP is a conjugate between the pain-processing peptide substance P and the ribosome-inactivating protein saporin.

    The mechanism of action of SP-SAP is well characterized, a rarity in pain therapeutics, according to Advanced Targeting Systems. A small number of cells that process pathological pain signals is removed, causing relief that appears to be permanent, the firm explains. Normal acute pain is unaffected.

    FDA recommended that the first population to undergo treatment with SP-SAP is terminal cancer patients who are resistant to opioids such as morphine. In preclinical tests, a single treatment with SP-SAP alleviated pathologic pain perception without affecting other sensory signal pathways.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »